Overview

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

Status:
Recruiting

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

This research study is evaluating a new type of Kidney Cancer vaccine called "Personalized NeoAntigen Cancer Vaccine"as a possible treatment for Kidney Cancer. The following intervention will be involved in this study: - Personalized Neoantigen Vaccine - Poly-ICLC (Hiltonol) - Ipilimumab

Phase:

Phase 1

Details

Lead Sponsor:

Dana-Farber Cancer Institute
Patrick Ott, MD

Collaborators:

Bristol-Myers Squibb
Oncovir, Inc.

Treatments:

Antibodies, Monoclonal
Ipilimumab
Vaccines